骨巨细胞瘤
Giant cell tumor of bone
定义
本病是一种罕见的骨肉瘤，其特征是通常为良性的占位性病变，但仍具有局部侵袭性，并会严重破坏周围的骨组织。该肿瘤由分泌髓样前体和破骨前因子的巨多核细胞（破骨细胞样细胞），单核巨噬细胞和单核基质细胞组成。转移和恶性转化很少见，但复发率很高。
别名
骨巨细胞瘤
基本事实
- 遗传方式
- 不适用
- 发病年龄
- 成年期
- 患病率
- 1-9 / 1 000 000
近两年的全球研究 455L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-08病例报告Custom 3D Implant for Hemiarthroplasty of the Third Metacarpal in a Giant Cell Tumor of bone: Functional Outcomes and Hand Stability
- 2026-08Fibulectomy for primary fibular tumors A Decade of experience at the National Cancer Institute, Egypt
- 2026-07病例报告A Rare Case of Giant Cell tumor of Bone in Distal Tibia
- 2026-07病例报告Giant Cell Tumor of the Cervical Axis Treated With Anterior-Posterior Surgery and Denosumab: A Ten-year Follow-up Case Report
- 2026-06Immunoexpression of CXCL12 and CXCR4 in giant cell granulomas of the jaws and giant cell tumor of bone
- 2026-06病例报告Giant Cell Tumor of the Lumbar Spine with Large Retroperitoneal Extension and Vascular Attachment
- 2026-06病例报告Secondary Malignant Transformation of Giant Cell Tumor of Bone Nine Years After Initial Curettage: A Case Report and Literature Review
- 2026-06病例报告Pheochromocytoma and multicentric giant cell tumor of bone
- 2026-06综述Incidence of malignant transformation in giant cell tumor of bone following denosumab therapy: a systematic review and meta-analysis
- 2026-06病例报告Recurrent Giant Cell Tumor of the Lateral Condyle of the Distal Femur Managed by Repeated Extended Curettage and Bone Cementing: A Case Report
- 2026-06Central Giant Cell Granuloma: A Decade of Institutional Experience and Curative Potential of Neoadjuvant Denosumab
- 2026-06ICG-based NIR fluorescence imaging can help to detect residual giant cell tumor of bone after intralesional curettage: Results of two-year follow-up
- 2026-06开放获取Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence
- 2026-06病例报告开放获取Optimal management of giant cell tumor in the tibial plateau: A case report on curettage and cement reinforcement
- 2026-06综述开放获取Hijacking the bone niche: mechanistic insights into bone metastasis in breast cancer
- 2026-06A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM)
- 2026-06病例报告开放获取A Case of Tumor-Induced Osteomalacia Masked by Parathyroid Carcinoma
- 2026-06Recurrence of Giant Cell Tumor of Bone and Related Risk Factors: A Retrospective Analysis of 340 Cases From a Single Center
- 2026-06[Interpretation of National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Bone Cancer (Version 2.2026): Updates in diagnosis and treatment strategies for giant cell tumor of bone, osteosarcoma, and Ewing sarcoma]
- 2026-06开放获取The Long-Term Quality of Life Study for Patients Received Chest Wall Reconstruction by Using 3D-Printed PEEK Implants
国家医保药品目录中点名本病的药品 1L2
出自《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（医保发〔2025〕33号，2026-01-01 起执行）。下列药品在药品名称或限定支付范围里出现了本病的名称。
匹配不到 ≠ 不能报销。目录里只有约一成药品设了限定支付范围，其余按适应症正常使用同样可报销；本区块只能回答「目录有没有点名这个病」，不能回答「这个病有没有药能报销」。各省执行细则、双通道与单独支付范围另有规定，请以当地医保部门口径为准。
- 纳鲁索拜单抗注射液乙类谈判药品限不可手术切除或手术切除可能导致严重功能障碍的骨巨细胞瘤成人患者。
境外已获批用于本病的药物 2L2
欧盟 1 项、美国 1 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 11L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 5
- 招募中NCT05595603Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage中国研究中心 1 个：Hangzhou
- 尚未开始招募NCT05813665A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone中国研究中心 1 个：Beijing
- 招募中NCT06302465Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells中国研究中心 1 个：Beijing
- 招募中NCT06647901Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study中国研究中心 1 个：Beijing
- 招募中NCT07315828Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery中国研究中心 1 个：Shanghai
其他状态的试验（6 项）
- 已完成NCT06331104Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone中国研究中心 1 个：Guangzhou
- 状态未知NCT03259152Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone中国研究中心 1 个：Shijiazhuang
- 状态未知NCT04255576Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone中国研究中心 1 个：Beijing
- 已完成NCT04952818The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine中国研究中心 1 个：Beijing
- 已完成NCT05402865A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone中国研究中心 3 个：Beijing
- 进行中·不再招募NCT04586660Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone中国研究中心 8 个：Beijing、Fuzhou、Guangzhou、Hangzhou、Harbin、Xi'an
中国境外的在招试验 10L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国4加拿大2捷克1印度1
CT.gov 报告命中 10 项，此处取回并展示最近的 5 项。
- 招募中NCT07609277TRACP-5b for Diagnosis and Follow-up of Giant Cell Tumor of Bone捷克
- 招募中NCT07227961PROMIS and Mobility Evaluation in Sarcoma Patients加拿大、美国
- 招募中NCT06239272NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)美国
- 招募中NCT05463796InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer美国
- 招募中NCT03295981Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone加拿大、印度、美国
外部标识与链接
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）